RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Liquidia Technologies today announced the presentation of data from two preclinical studies at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. The ARVO annual meeting is the largest and most respected eye and vision research conference in the world, drawing nearly 13,000 researchers from over 80 countries. The two poster presentations are as follows:
Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone - Andres Garcia, Janet Tully, Benjamin Maynor, Benjamin Yerxa. Liquidia Technologies, Durham, NC.
Application of PRINT Microparticle and Nanoparticle Technology Toward Preparation of Ophthalmic Suspension Formulations with Improved Tolerability and Efficacy - Benjamin Maynor, Andres Garcia, Janet Tully, Benjamin Yerxa. Liquidia Technologies, Research Triangle Park, NC.
Earlier this month, Liquidia Technologies announced its intent to form a new ophthalmology-focused. While specific details for the new company will be disclosed at a later date, Liquidia has indicated that the lead product for the new ophthalmology company is being developed to treat glaucoma and is expected to initiate clinical studies in 2014. The PRINT technology offers the unique ability to develop novel small or large molecule formulations with extended release formulations that address critical dosing and compliance challenges for patients and physicians.
The creation of this new company builds on the success that Liquidia has recently had with vaccines and pulmonary products, including significant partnerships with GlaxoSmithKline and PATH, a global health nonprofit organization.
ABOUT LIQUIDIA TECHNOLOGIES
Liquidia Technologies, founded in 2004, is a privately held biotechnology company located in Research Triangle Park, North Carolina. By leveraging precise fabrication techniques of the semiconductor industry, Liquidia has become the only company in the world with the ability to rapidly design and manufacture precisely engineered particles of virtually any size, shape, or composition using a unique particle engineering and manufacturing platform known as the PRINT® platform. This unique ability to precisely engineer particles enables scientists to explore new product frontiers that, until now, have otherwise been out of reach for the life sciences industry. Liquidia and its partners are currently exploring the application of this novel technology to development of products in several high growth areas such as vaccines, pulmonology, oncology and ophthalmology. In addition to the development of its own products, Liquidia licenses its PRINT particle technology and its cGMP manufacturing capabilities to support proprietary programs advanced by collaborators. For more information, please go to www.liquidia.com.
